이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bright Minds Biosciences 관리

관리 기준 확인 1/4

Bright Minds Biosciences' CEO는 Ian McDonald, May2019 에 임명되었습니다 의 임기는 5.08 년입니다. 는 CA$ 1.35M 가치에 해당하는 회사 주식의 21.84% 직접 소유합니다. 1.35M. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 2.1 년입니다.

주요 정보

Ian McDonald

최고 경영자

CA$626.2k

총 보상

CEO 급여 비율	n/a
CEO 임기	5.2yrs
CEO 소유권	21.8%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	2.2yrs

최근 관리 업데이트

Recent updates

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

CEO

Ian McDonald (35 yo)

5.2yrs

테뉴어

CA$626,178

보상

Mr. Ian McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executive Officer since June 06, 2020 and serves as its President and Director since May 31, 2019. He served as Presi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ian McDonald	Co-Founder	5.2yrs	CA$626.18k	21.84% CA$ 1.3m
Ryan E. S. Cheung	Chief Financial Officer	4.2yrs	CA$120.00k	0% CA$ 0
Jan Pedersen	Chief Science Officer & Director	1.8yrs	CA$799.72k	0% CA$ 0
Mark Smith	Chief Medical Officer	1.6yrs	CA$505.51k	데이터 없음
Emer Leahy	Consultant	2.2yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: DRUG 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ian McDonald	Co-Founder	5.2yrs	CA$626.18k	21.84% CA$ 1.3m
Jan Pedersen	Chief Science Officer & Director	2.3yrs	CA$799.72k	0% CA$ 0
Robert Malenka	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음
Herbert Meltzer	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음
David Weiner	Independent Non-Executive Director	1.4yrs	CA$22.04k	0% CA$ 0
Jeremy Fryzuk	Independent Director	3.8yrs	CA$7.69k	0.054% CA$ 3.3k
Nils Bottler	Independent Director	3.8yrs	CA$7.69k	0.090% CA$ 5.5k
Michael Bogenschutz	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음
Peter Hendricks	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

39yo

평균 연령

경험이 풍부한 이사회: DRUG 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Bright Minds Biosciences 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Recent updates

New major risk - Financial position

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding

New major risk - Market cap size

Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101

Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101

Less than half of directors are independent

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Bright Minds Biosciences Inc., Annual General Meeting, Mar 24, 2023

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

Bright Minds Biosciences Inc. announced that it expects to receive CAD 2.05 million in funding

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer, Effective December 1, 2022

High number of new and inexperienced directors

Bright Minds Biosciences Announces Executive Changes

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Bright Minds Biosciences Announces Changes to Its Executive Leadership Team

High number of new and inexperienced directors

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Bright Minds Biosciences Provides Scientific Update on Its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

High number of new and inexperienced directors

Bright Minds Biosciences Inc. Provides Scientific Update

CEO & Director recently bought CA$116k worth of stock

Bright Minds Biosciences Inc., Annual General Meeting, May 18, 2021

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 25.00371 million.

Bright Minds Biosciences Inc. Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences Announces Scientific Advisory Team Appointment

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령